The LIT - Leibniz Institute for Immunotherapy (foundation under civil law) (https://lit.eu) – is a biomedical research center focusing on translational immunology in the fields of cancer immunotherapy, transplant rejection and autoimmunity. The objective of the LIT is to develop innovative and efficient cellular immune therapeutics in these areas. Our own GMP laboratories and close networking with University and University Hospital offer excellent opportunities for clinical translation of novel immune cell products.
The Group “Epigenetic Immunooncology” at the LIT is recruiting a
in part-time position (E13, 65%), starting as soon as possible. This position is initially limited to three years, with the possibility of extension.
The Schmidl lab works at the interface of immunology and cancer, which is one of the most exciting fields of recent biomedical research. We provide a dynamic and motivating working environment with flat hierarchies where you can foster your skills and get the opportunity to use top-notch technologies. The small lab size offers excellent mentoring and training opportunities.
About the project
Our group investigates the principles of gene-regulation in functional and dysfunctional immune cell populations in cancer (Riegel et al. 2023 Molecular Cell). In this project, you will investigate the cross-talk of the tumor microenvironment with molecular mechanisms of T cell (dys-)function. You will explore next-generation CRISPR methods to manipulate proteins in primary immune cells to map and perturb molecular interactions and signaling processes.
Your Tasks
Handling of primary human and murine immune cells
Build on existing expertise to use and further develop CRISPR (epi-)genome editing
Using cellular (e.g., FACS) and molecular (e.g., single cell analysis, next generation sequencing) methods to characterize immune cells
Using biochemistry approaches to study proteins
Test the function of modified immune cells in advanced in vitro systems and/or murine disease models
Our Requirements
We are looking for a highly motivated individual who is enthusiastic to work in a young and ambitious team on a competitive project, and who fits the following profile:
Strong interest in immunology & cancer
Master in biology/biochemistry/molecular medicine or related fields
Creative mind that is eager to shape the project and who wants to make an impact on immunological and biomedical research
Experimental training in molecular biology and immunology
Keen interest in using modern technology
Excellent oral and written communication skills and team spirit
Experience in CRISPR base-editing required
Experience in mouse models (FELASA certificate), and next generation sequencing methods advantageous but not absolutely required
We offer:
A varied and exciting role in an innovative research environment
A dynamic and dedicated team committed to the future of cell therapies
Comprehensive training on state-of-the-art methods
Flat hierarchies and short decision-making processes
Excellent opportunities for professional and personal development
Flexible working hours to help balance family and career
Company pension scheme (VBL)
Annual special payment
Capital-forming benefits
Job ticket, and more
Remuneration is in accordance with TV-L (E13, 65%).
The LIT places particular emphasis on promoting a healthy work-life balance.
Applicants with severe disabilities (m/f/d) will be given preference in the event of essentially equal suitability. Please indicate any disability in your application.
Please note that expenses that may arise in the context of an eventual job interview cannot be reimbursed.
For more information, please contact Dr. Christian Schmidl (christian.schmidl@ukr.de).
We are looking forward to receiving your detailed application. Please apply via our Online - Application Portal quoting the reference CS-2025-02. Application deadline is November 26, 2025.